Skip to Main Content
Welcome to the Scientist.com Marketplace

Go to Main Navigation

101914

PI3 Kinase p110α (H1047L)/p85α, FLAG-Tag Recombinant

BPS Bioscience

DESCRIPTION

Recombinant human PI3 Kinase complex of p110α, with an H1047L mutation, and p85α variant 1. Subunit p110α encompasses amino acids 2-1068(end), and an N-terminal FLAG tag. Subunit p85α encompasses amino acids 1-724(end). The two constructs were expressed together, and the complex was affinity purified.

DETAILS

  • Aa: p110α: (2-1068(end)); p85α: (1-724(end))
  • Mw: p110α: 125 kDa; p85α: 84 kDa
  • Tags: p110α: N-Terminal FLAG Tag
  • Format: Aqueous buffer solution
  • Purity: ≥90%
  • Genbank: p110α: NM_006218; p85α: NM_181523
  • Species: Human
  • Uniprot: p110α (H1047R): P42336; p85α: P27986
  • Shiptemp: -80°C (dry ice)
  • Synonyms: Serine/threonine protein kinase PIK3CA, p110α, p110-alpha, PI3K-alpha, PtdIns-3-kinase subunit p110-alpha, MCM, CCM4, CWS5, MCAP, PI3K, CLAPO, CLOVE, MCMTC, PIK3R1, PtdIns-3-kinase regulatory subunit alpha, AGM7, GRB1, p85, p85-ALPHA
  • Warnings: Avoid freee/thaw cycles
  • Category: DNA Replication and Repair
  • Background: PI3 (phosphoinositide 3) kinases, or phosphatidylinositol 3 kinases, are a family of proteins that can be subdivided into four classes: I, II, III and IV. Class I is involved in converting PI (4, 5) P2 (phosphatidylinositol (4, 5)-biphosphate) into PI (3, 4, 5) P3 (phosphatidylinositol (3, 4, 5)-triphosphate) when activated by tyrosine kinase receptors and G-protein coupled receptors. They are heterodimeric proteins with a regulatory and a catalytic subunit. The heterodimer between p110 (catalytic subunit) and p85 (regulatory subunit) belongs to class IA. P110 and p85 have three variants each. P110α is ubiquitously expressed, and p85α is the most abundant variant of p85. Class I PI3K participates in cell signaling, mostly via the activation of PKB (protein kinase B) and the PI3K/AKT/mTOR pathway. Dysfunction of these kinases impacts cell growth and differentiation, and mutations in p110α have been linked to cancer. At least three isoform-specific inhibitors are approved by FDA for the treatment of lymphoma and leukemia. Further studies will help identify more selective inhibitors with a good tolerance that can bypass the development of drug resistance.
  • Constructs: p110α (H1047L) (FLAG-2-1068(end)) / p85α (1-724(end))
  • Description: Recombinant human PI3 Kinase complex of p110α, with an H1047L mutation, and p85α variant 1. Subunit p110α encompasses amino acids 2-1068(end), and an N-terminal FLAG tag. Subunit p85α encompasses amino acids 1-724(end). The two constructs were expressed together, and the complex was affinity purified.
  • Formulation: 25 mM Tris-HCl, pH 8.0, 69 mM NaCl, 1.35 mM KCl, 0.025% Tween-20, 50% glycerol, and 3 mM DTT
  • Unspsc Code: 12352202
  • Unspsc Name: Proteins
  • Applications: Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
  • Host Species: Sf9
  • Product Type: Protein
  • Biosafety Level: Not applicable (BSL-1)
  • Assay Conditions: Assay was done according to Chemi-Verse™ PI3 Kinase p110α (H1047L)/p85α Kinase Assay Kit (BPS Bioscience #82120) with various concentrations of PI3 Kinase p110α (H1047L)/p85α.
  • Related Products: 40620, 82103, 82108
  • Storage Stability: At least 6 months at -80°C
  • Scientific Category: Kinases
  • Instructions for Use: Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.